Significance of Interleukin-6 in Papillary Thyroid Carcinoma

Table 4

(a) Univariate survival analysis of circulating IL-6, its tumoral protein expression, and mRNA in primary tumours and adjacent normal tissues for DFS in PTC patients. (b) Univariate survival analysis of circulating IL-6, its tumoral protein expression, and mRNA in primary tumours and adjacent normal tissues for OS in PTC patients.

(a)

IL-6		Patients relapsed; (%)	Log rank test statistics
Circulating levels	69
Low	37	3 (8)	Log rank = 0.330, df = 1, = 0.565
High	32	4 (12)
Tumoral protein expression	69
Low	35	2 (6)	Log rank = 1.480, df = 1, = 0.224
High	34	5 (15)
mRNA expression; (primary tumour tissues)	54
Low	25	2 (8)	Log rank = 0.119, df = 1, = 0.730
High	29	3 (10)
mRNA expression; (adjacent normal tissues)	54
Low	32	3 (9)	Log rank = 0.003, df = 1, = 0.958
High	22	2 (9)

(b)

IL-6		Patients died; (%)	Log rank test statistics
Circulating levels	76
Low	37	1 (3)	Log rank = 4.772, df = 1,
High	39	7 (18)
Tumoral protein expression	76
Low	38	4 (10)	Log rank = 0.001, df = 1, = 0.977
High	38	4 (10)
mRNA expression; (primary tumour tissues)	60
Low	30	5 (17)	Log rank = 1.496, df = 1, = 0.221
High	30	2 (7)
mRNA expression; (adjacent normal tissues)	60
Low	34	3 (9)	Log rank = 0.748, df = 1, = 0.387
High	26	4 (15)